Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Headquartered in New Haven, CT Fiscal year ends December NASDAQ: ARVN arvinas.com
Arvinas is a clinical-stage biotechnology company that develops targeted protein degradation therapies using its PROTAC (PROteolysis TArgeting Chimera) platform. Its drugs are designed to harness the body's natural protein disposal system to eliminate disease-causing proteins rather than merely inhibit them.
With Pfizer, Arvinas developed vepdegestrant (VEPPANU), an ER degrader for breast cancer. It received FDA approval in May 2026 as the first approved PROTAC. It has since been out-licensed to Rigel Pharmaceuticals, from which Arvinas receives royalties and is eligible for milestones.
The AR degrader luxdegalutamide is out-licensed to Novartis and is in Phase 2 prostate cancer trials.
Arvinas's wholly owned clinical pipeline includes:
- **ARV-393:** BCL6 degrader for relapsed/refractory non-Hodgkin lymphoma, alone and with glofitamab.
- **ARV-6723:** HPK1 degrader, an immuno-oncology asset for advanced solid tumors, alone and with pembrolizumab.
- **ARV-027:** polyQ-AR degrader for spinal-bulbar muscular atrophy (Kennedy's disease).
- **ARV-102:** brain-penetrant LRRK2 degrader for progressive supranuclear palsy and Parkinson's disease.
The company is seeking to out-license its KRAS G12D degrader ARV-806. Revenue currently comes from partner royalties, milestones and license payments. Updated
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Here are the top analysts calls for Friday, November 25.
Tuesday's top analyst upgrades and downgrades included Apple, Chipotle Mexican Grill, Citigroup, Constellation Energy, Fastenal, JPMorgan Chase, Kroger, Livent, News Corp, Prologis, Salesforce and SunPower.
Tuesday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Costco Wholesale, Dollar General, Exxon Mobil, FedEx, Horizon Therapeutics, Hyatt Hotels, Lucid, Medtronic, Micron Technology, Salesforce, Six Flags Entertainment, Tellurian and Unity Software.
Monday’s additional top analyst upgrades and downgrades were on Domino’s, iHeartMedia, Match Group, Virgin Galactic and more.
Arvinas is a clinical-stage biotechnology company that develops targeted protein degradation therapies using its PROTAC (PROteolysis TArgeting Chimera) platform. Its drugs are designed to harness the body's natural protein disposal system to eliminate disease-causing proteins rather than merely inhibit them.
The Wall Street consensus 12-month price target for ARVN is $14.00. ARVN price prediction →